CN112930181B - 小分子cd-47抑制剂与其它抗癌剂的组合 - Google Patents

小分子cd-47抑制剂与其它抗癌剂的组合 Download PDF

Info

Publication number
CN112930181B
CN112930181B CN201980071532.5A CN201980071532A CN112930181B CN 112930181 B CN112930181 B CN 112930181B CN 201980071532 A CN201980071532 A CN 201980071532A CN 112930181 B CN112930181 B CN 112930181B
Authority
CN
China
Prior art keywords
cancer
sirpa
compound
certain embodiments
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980071532.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112930181A (zh
Inventor
穆拉利达拉·拉马钱德拉
波塔伊尔·戈文丹·奈尔·萨斯库马
G·C·达吉纳卡特
K·A·巴尔库德鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregini Oncology Co ltd
Aurigene Oncology Ltd
Original Assignee
Oregini Oncology Co ltd
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregini Oncology Co ltd, Aurigene Discovery Technologies Ltd filed Critical Oregini Oncology Co ltd
Priority to CN202510514794.1A priority Critical patent/CN120305258A/zh
Publication of CN112930181A publication Critical patent/CN112930181A/zh
Application granted granted Critical
Publication of CN112930181B publication Critical patent/CN112930181B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980071532.5A 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合 Active CN112930181B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510514794.1A CN120305258A (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510514794.1A Division CN120305258A (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Publications (2)

Publication Number Publication Date
CN112930181A CN112930181A (zh) 2021-06-08
CN112930181B true CN112930181B (zh) 2025-05-13

Family

ID=69159806

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980071532.5A Active CN112930181B (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合
CN202510514794.1A Pending CN120305258A (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510514794.1A Pending CN120305258A (zh) 2018-11-08 2019-11-08 小分子cd-47抑制剂与其它抗癌剂的组合

Country Status (14)

Country Link
US (3) US11311517B2 (https=)
EP (1) EP3876931A1 (https=)
JP (2) JP7623279B2 (https=)
KR (1) KR20210088584A (https=)
CN (2) CN112930181B (https=)
AU (1) AU2019375193A1 (https=)
BR (1) BR112021008781A2 (https=)
CA (1) CA3118843A1 (https=)
EA (1) EA202190776A1 (https=)
IL (1) IL282972B2 (https=)
MX (2) MX2021005240A (https=)
PH (1) PH12021550832A1 (https=)
SG (1) SG11202104192TA (https=)
WO (1) WO2020095256A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
EP4291238A4 (en) * 2021-02-10 2024-10-09 Great Novel Therapeutics Biotech & Medicals Corporation PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING AN IMMUNE RESPONSE AGAINST CANCER
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
WO2025083628A1 (en) 2023-10-19 2025-04-24 Aurigene Oncology Limited Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
US20250339404A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142833A1 (en) * 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018073754A1 (en) * 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Dual inhibitors of vista and pd-1 pathways

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672828A1 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
EP3267985A4 (en) 2015-03-10 2018-07-25 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
DK3454879T3 (da) 2016-05-10 2022-03-14 Inst Nat Sante Rech Med Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
WO2019175799A2 (en) * 2018-03-14 2019-09-19 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142833A1 (en) * 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018073754A1 (en) * 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Dual inhibitors of vista and pd-1 pathways

Also Published As

Publication number Publication date
CA3118843A1 (en) 2020-05-14
IL282972B1 (en) 2025-02-01
IL282972A (en) 2021-06-30
EP3876931A1 (en) 2021-09-15
CN112930181A (zh) 2021-06-08
AU2019375193A1 (en) 2021-05-13
JP2022507025A (ja) 2022-01-18
US20250177358A1 (en) 2025-06-05
EA202190776A1 (ru) 2021-09-20
US20220241248A1 (en) 2022-08-04
JP2025063207A (ja) 2025-04-15
KR20210088584A (ko) 2021-07-14
US20200147054A1 (en) 2020-05-14
US12268670B2 (en) 2025-04-08
JP7623279B2 (ja) 2025-01-28
IL282972B2 (en) 2025-06-01
BR112021008781A2 (pt) 2021-08-03
SG11202104192TA (en) 2021-05-28
MX2021005240A (es) 2021-06-18
US11311517B2 (en) 2022-04-26
MX2024006094A (es) 2024-05-30
WO2020095256A1 (en) 2020-05-14
PH12021550832A1 (en) 2021-10-04
CN120305258A (zh) 2025-07-15

Similar Documents

Publication Publication Date Title
CN112930181B (zh) 小分子cd-47抑制剂与其它抗癌剂的组合
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
JP7438955B2 (ja) Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物
CA3085634C (en) A conjugate of a tubulysin analog with branched linkers
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
EA026406B1 (ru) Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и бортезомиб
KR20180059544A (ko) 글루타미나제 억제제와 면역-종양학적 약제에 의한 병용 요법
JP7417804B2 (ja) １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法
WO2018047143A1 (en) Vista signaling pathway inhibitory compounds useful as immunomodulators
CN121398817A (zh) 治疗具有先前免疫检查点抑制剂暴露的受试者的癌症的方法
TW202434300A (zh) 藥物綴合物及其製備與使用方法
EA045738B1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
EA044002B1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
EA049945B1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
HK40015605A (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: bangalore

Applicant after: Oregini Oncology Co.,Ltd.

Address before: bangalore

Applicant before: AURIGENE DISCOVERY TECHNOLOGIES Ltd.

GR01 Patent grant
GR01 Patent grant